Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27859860 | 0.95 | EGFR (0.49) | EGFRSIGMAR1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL21465934 | 0.88 | ALDH1A1 (0.43) | EGFRSIGMAR1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28098062 | 0.82 | ALDH1A1 (0.49) | SIGMAR1ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL21590285 | 0.81 | GAA (0.57) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL21490455 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2MEN1MAPT | |
| Hydrochloric Acid SCHEMBL28283970 | 0.81 | ALDH1A1 (0.54) | EGFRALDH1A1KDM4ESMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL28820059 | 0.80 | ALDH1A1 (0.56) | EGFRALDH1A1KDM4ESMN1; SMN2MEN1 | |
| Bromide SCHEMBL14247934 | 0.79 | EGFR (0.52) | EGFRSIGMAR1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL653787 | 0.79 | ALDH1A1 (0.46) | EGFRALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL24177783 | 0.78 | KMT2A (0.58) | ALDH1A1KDM4ESMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166301-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180207298-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2018-07-26 | — | — | US | disclosed |
| US-9974869-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2018-05-22 | — | — | US | disclosed |
| EP-2721039-B1 | CHELATED PSMA INHIBITORS | CANCER TARGETED TECH LLC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20170072075-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2017-03-16 | — | — | US | disclosed |
| US-9446157-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140241985-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207298-A1 | Chelated PSMA Inhibitors | FOLH1, KLK3, PSMA1 | SIGMAR1 3316/4885EGFR 810/4885ALDH1A1 1059/4885 |
| US-10166301-B2 | Chelated PSMA inhibitors | FOLH1, KLK3, PSMA1 | SIGMAR1 3316/4885EGFR 810/4885ALDH1A1 1059/4885 |
| US-20170072075-A1 | Chelated PSMA Inhibitors | FOLH1, KLK3, PSMA1 | SIGMAR1 3316/4885EGFR 810/4885ALDH1A1 1059/4885 |
| US-20140241985-A1 | Chelated PSMA Inhibitors | FOLH1, KLK3, PSMA1 | SIGMAR1 3316/4885EGFR 810/4885ALDH1A1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.